Differential molecular pathway expression according to chemotherapeutic response in ovarian clear cell carcinoma

BMC Women's Health

Table 1 Clinicopathological features of the patients

Patient ID	Age	Preoperative CA125 (U/mL)	NACT	FIGO stage	Residual disease	Chemotherapy regimen	Chemotherapy cycles
OCCC-PR-01	51	1013	-	III	R0	TC	6
OCCC-PR-02	52	186.2	-	III	R1	TC	6
OCCC-PR-03	35	82.2	-	II	R0	TC	6
OCCC-PR-04	47	11.5	-	II	R0	TC	6
OCCC-PR-05	47	147.1	-	III	R0	TC	6
OCCC-PR-06	41	68.3	TC×3	IV	R2	TC	6
OCCC-PR-07	50	123.4	-	II	R0	TC	6
OCCC-PR-08	52	598.2	-	III	R0	TC	6
OCCC-PR-09	32	302	-	III	R0	TC	6
OCCC-PR-10	43	555.9	TC×1	III	R2	TC	6
OCCC-PR-11	58	390	-	III	R1	TC	6
OCCC-PR-12	31	260	-	II	R0	DDP + CTX*	1 + 6
OCCC-PS-01	65	204.3	-	II	R0	TC	6
OCCC-PS-02	52	115.8	-	II	R0	TC	6
OCCC-PS-03	57	11.8	-	III	R0	TC	6
OCCC-PS-04	51	54.7	-	III	R1	TC	6
OCCC-PS-05	42	30.5	-	II	R0	TC	6
OCCC-PS-06	58	229	-	III	R1	TC	6
OCCC-PS-07	51	29.3	-	III	R0	TC	6
OCCC-PS-08	51	43.3	-	III	R1	TC	6
OCCC-PS-09	51	1952	TC×3	IV	R2	TC	6
OCCC-PS-10	43	69.3	-	III	R0	TC	6
OCCC-PS-11	27	45	-	II	R0	TC	6
OCCC-PS-12	51	59	TC×2	III	R2	TC	6

Abbreviations: NACT, neoadjuvant chemotherapy; R, residual disease; R0, no macroscopic residual disease; R1, macroscopic residual disease with a maximal diameter < 1 cm; R2, macroscopic residual disease with a maximal diameter > 1 cm; TC, paclitaxel and carboplatin; DDP, cisplatin; CTX, cyclophosphamide
* This patient experienced an allergic reaction to paclitaxel and was subsequently treated with cisplatin and cyclophosphamide for 6 cycles

ISSN: 1472-6874